All In Biotech

Drug Trial Radar · NCT03994731

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA® (Pegloticase) (MIRROR Randomized Controlled Trial [RCT])

Last checked: Nov 20, 2026Latest source record: Jun 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

152

Actual

Start

Jun 13, 2019

Primary completion

Mar 17, 2021

Study completion Apr 11, 2022

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jun 21, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the potential for pegloticase with methotrexate (MTX) to increase the response rate seen with pegloticase alone, and to characterize the safety, tolerability and pharmacokinetics (PK) of the concomitant use of pegloticase with MTX, by comparing pegloticase co-administered with MTX to pegloticase co-administered with placebo for MTX in adults with uncontrolled gout.

Conditions

  • Gout

Interventions

  • PegloticaseBiological

    IV pegloticase 8 mg Q2W

  • methotrexateDrug

    Oral MTX 15 mg weekly

  • placeboDrug

    Oral placebo for MTX

  • folic acidDietary supplement

    Folic acid 1 mg orally every day beginning at Week -6 until prior to the Week 52 Visit.

  • gout flare prophylaxis regimenDrug

    Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al. 2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.

  • fexofenadineDrug

    For IR prophylaxis, fexofenadine (180 mg orally) taken the day before each infusion and on the morning of each infusion.

  • acetaminophenDrug

    For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.

  • methylprednisoloneDrug

    For IR prophylaxis, methylprednisolone (125 mg IV) given over an infusion duration between 10 - 30 minutes, immediately prior to each infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6Time frame: Month 6 (Weeks 20, 21, 22, 23 and 24)

Locations

60 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • Orthopedic Physicians Alaska

    Anchorage, Alaska

  • Arizona Arthritis and Rheumatology Research, PLLC - Flagstaff

    Flagstaff, Arizona

  • Arizona Arthritis and Rheumatology Research, PLLC-West

    Glendale, Arizona

  • Arizona Arthritis and Rheumatology Research, PLLC-East

    Mesa, Arizona

  • Applied Research Center of Arkansas, Inc

    Little Rock, Arkansas

  • TriWest Research Associates

    El Cajon, California

  • Advanced Investigative Medicine, Inc.

    Hawthorne, California

  • Axis Clinical Trials

    Los Angeles, California

  • ACRC Studies

    Poway, California

  • ClinEdge Sierra Rheumatology, Inc.

    Roseville, California

  • East Bay Rheumatology Medical Group, Inc.

    San Leandro, California

  • Providence St. John's Health Clinic

    Santa Monica, California

  • Medvin Clinical Research

    Tujunga, California

  • San Fernando Valley Health Institute

    Van Nuys, California

  • Ventura Clinical Trials

    Ventura, California

  • University of Colorado Division of Rheumatology

    Aurora, Colorado

  • Denver Arthritis Clinic

    Denver, Colorado

  • Avail Clinical Research

    DeLand, Florida

  • Prohealth Research Center

    Doral, Florida

  • Omega Research Maitland

    Orlando, Florida

  • DMI Research

    Pinellas Park, Florida

  • Napa Research Center

    Pompano Beach, Florida

  • GCP Clinical Research

    Tampa, Florida

  • Florida Medical Clinic, LLC

    Zephyrhills, Florida

  • St. Luke's Clinic - Rheumatology

    Meridian, Idaho

  • MD Medical Research

    Oxon Hill, Maryland

  • The Center for Rheumatology and Bone Research

    Wheaton, Maryland

  • Infusion Associates

    Grand Rapids, Michigan

  • Clinical Research Institute of Michigan, LLC

    Saint Clair Shores, Michigan

  • Benefis Hospital

    Great Falls, Montana

  • Physician Research Collaboration, LLC

    Lincoln, Nebraska

  • Santa Fe Rheumatology

    Santa Fe, New Mexico

  • Long Island Arthritis & Osteoporosis Care

    Babylon, New York

  • Buffalo Rheumatology and Medicine

    Orchard Park, New York

  • NorthEast Rheumatology/Atrium Health

    Concord, North Carolina

  • NorthEast Rheumatology

    Concord, North Carolina

  • Medication Management, LLC

    Greensboro, North Carolina

  • ClinEdge PMG Research of Hickory, LLC

    Hickory, North Carolina

  • ClinEdge PMG Research of Salisbury, LLC

    Salisbury, North Carolina

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.